FEATURED NEWS

• Analysis of Specialty Distributors Reveals Continued Growth

  December 13, 2019

  A new analysis published by the HDA Research Foundation indicates that oncology drugs, autoimmune and HIV therapeutics fueled specialty pharmaceutical segment growth in 2018. The 2019 Specialty Pharmaceutical Distribution: Facts, Figures and Trends indicates that oncology therapeutics account for most specialty distributor sales at 48.4 percent.

• Pharmaceutical Sales Through Primary Distributors Reach $493 Billion

  December 6, 2019

  In 2018, sales through pharmaceutical distributors increased by 6.7 percent, reaching $492.54 billion, according to a new report by the HDA Research Foundation. The 90th Edition HDA Factbook: The Facts, Figures and Trends in Healthcare (2019–2020) also notes that chain drug stores were the largest customer base for pharmaceutical wholesalers — accounting for 44.6 percent of all sales, a slight increase from 2017. Distributor margins, however, continued a four-year slide, though they showed increases in efficiency.

• HDA Statement on Proposed DEA Regulations

  October 28, 2019

  In response to the Drug Enforcement Administration’s (DEA) proposed regulations related to the review and monitoring of annual production quotas, the Healthcare Distribution Alliance (HDA) released the following statement.

• Drew and Mauch Reelected to Lead HDA Board of Directors

  October 21, 2019

  The Healthcare Distribution Alliance (HDA) announced that Greg Drew, RPh, President of Value Drug Company, and Robert Mauch, PhD, PharmD, EVP and Group President of AmerisourceBergen Corporation, were recently elected to second terms as Chairman and Vice Chairman of the HDA Board of Directors.

• HDA Statement on the Ensuring Patient Access and Effective Drug Enforcement Act

  September 13, 2019

  The Healthcare Distribution Alliance (HDA) released the following statement regarding media reporting on the Ensuring Patient Access and Effective Drug Enforcement Act of 2016.